Lung Cancer

An immune checkpoint inhibitor plus ramucirumab found to improve overall survival versus standard of care in patients with advanced non-small cell lung cancer.

Uliledlimab plus toripalimab (Tuoyi) shows significant response rates in patients with advanced non–small cell lung cancer previously ineligible to receive standard-of-care treatment.

Company releases data at the American Society of Clinical Oncology Annual Meeting 2022 showing that the drug is well-tolerated in patients with solid tumors.

Repotrectinib awarded breakthrough therapy designation for patients with ROS1-positive metastatic non–small cell lung cancer previously treated with a ROS1 tyrosine kinase inhibitor and who were not previously administered platinum-based chemotherapy.

The SKYSCRAPER-01 trial evaluating the drug plus Tecentriq demonstrates that it did not meet its co-primary endpoint of progression-free survival.

The agent is the first oral therapy for this indication.

Additionally, the safety profile in DESTINY-Lung01 was consistent with previous clinical trials with no new safety concerns identified.

The investigational selective, covalent, and orally bioavailable KRASG12C¬ inhibitor shows a 57% confirmed overall response rate at the recommended dose of 200 mg twice daily.

Based on event-free survival and pathologic complete response results, the FDA approved nivolumab in combination with platinum-doublet chemotherapy in March 2022.

Results show that 64% of individuals treated with lorlatinib were without disease progression after 3 years compared with about 19% of those treated with crizotinib (Xalkori).

Clinical data from phase 1/2 LIBRETTO trial show evidence of meaningful clinical outcomes for patients, including those with difficult-to-treat brain metastases.

Sotorasib demonstrates clinical benefit and prolonged tumor response seen, with a 40.7% objective response rate.

Melissa Johnson, MD, program director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses her presentation at the Community Oncology Alliance 2022 conference on new drugs in the non-small cell lung cancer space.

Pharmacist interactions provide significant benefits for patients with non-small cell lung cancer treated with oral oncolytics.

The Roche subsidiary reports that it will continue to evaluate tiragolumab plus Tecentriq and chemotherapy in non-small cell lung cancer and other cancer types through more phase 3 trials.

Osimertinib (Tagrisso; AstraZeneca) is FDA approved for 3 unique cancer indications.

Ramucirumab (Cyramza; Eli Lilly) is FDA-approved for 5 unique cancer indications.

Poziotinib demonstrates positive results for treatment-naïve patients with non-small cell lung cancer harboring HER2 exon 20 insertion mutations.

Nivolumab (Opdivo) plus platinum-doublet chemotherapy approved for the treatment of adult patients with resectable non–small cell lung cancer in the neoadjuvant setting.

Acceptance is based on CheckMate -816 trial results where the agency granted priority review status to the Bristol Myers Squibb drug and assigned a PDUFA goal date of July 13, 2022.

FDA to evaluate adagrasib for the treatment of patients with non–small cell lung cancer with tumors that have a KRAS G12C mutation.

All the participants were in the Beating Lung Cancer in Ohio study, which started before the COVID-19 pandemic.

Clinical benefits were seen across subgroups, including patients with squamous and non-squamous lung cancer subtypes, and regardless of PD-L1 levels.

The sBLA is reinforced by results from a randomized phase 3 trial that investigated cemiplimab-rwlc in combination with a physician’s choice of platinum-doublet chemotherapy compared to platinum-doublet chemotherapy alone.

The findings from the phase 3 KEYNOTE-091 trial mark the first positive study for pembrolizumab in adjuvant stage IB-IIIA non-small cell lung cancer.

Patients with EGFR exon 20 insertion mutation NSCLC account for approximately 1%-2% of NSCLC cases.

In the first quarter of 2022, Genprex expects to initiate its Acclaim-2 clinical trial to evaluate the treatment for individuals with histologically confirmed unresectable stage III or IV non–small cell lung cancer.

Telisotuzumab vedotin (Teliso-V, AbbVie) is an investigational antibody-drug conjugate that targets c-Met, a receptor tyrosine kinase that is overexpressed in tumors.

The Breakthrough Therapy Designation was granted based on data from the dose escalation portion of 2 expansion cohorts of a 3-cohort phase 1 study.

Commonly used medications may influence responses to checkpoint inhibitors among patients with cancer.